Do physicians tailor their recommendations for breast cancer risk reduction based on patient's risk?

Journal of General Internal Medicine

Volumn 19, Issue 4, 2004, Pages 302-309

  Haas, Jennifer S ^a   Kaplan, Celia P ^b   Gregorich, Steven E ^b   Pérez Stable, Eliseo J ^b   Des Jarlais, Genevieve ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Breast cancer; Physician survey; Prevention; Risk reduction

Indexed keywords

TAMOXIFEN;

ADULT; AGED; BREAST CANCER; CANCER PATIENT; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CLINICAL ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DISEASE COURSE; DRUG UTILIZATION; FAMILY HISTORY; FEMALE; GENETIC ANALYSIS; GENETIC SCREENING; GYNECOLOGY; HEALTH BEHAVIOR; HIGH RISK PATIENT; HUMAN; LIFESTYLE; MAMMOGRAPHY; MEDICAL SPECIALIST; PATIENT COUNSELING; PATIENT REFERRAL; PHYSICIAN; POSTAL MAIL; PRIMARY MEDICAL CARE; RANDOMIZATION; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SAMPLE; STANDARD;

ADULT; BREAST NEOPLASMS; COUNSELING; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; LIFE STYLE; LINEAR MODELS; MAMMOGRAPHY; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; RISK ASSESSMENT; RISK REDUCTION BEHAVIOR;

EID: 1942499770     PISSN: 08848734     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1525-1497.2004.30280.x     Document Type: Review

References (46)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1997. CA Cancer J Clin. 1997;47:5-27.
2. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266:66-71.
3. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90:1371-88.
4. Hartmann LC, Schaid DJ, Woods JE, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med. 1999;340:77-84.
5. Hartmann LC, Sellers TA, Schaid DJ, et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst. 2001;93:1633-7.
6. Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomized chemoprevention trial. Lancet. 1998;352:98-101.
7. Veronesi U, Maisonneuve P, Costa A, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomized trial among hysterectomized women. Italian Tamoxifen Prevention Study. Lancet. 1998;352:93-7.
8. Shapiro S. Periodic screening for breast cancer: the HIP Randomized Controlled Trial. Health Insurance Plan. J Natl Cancer Inst. 1997;22:27-30.
9. Tabar L, Chen HH, Fagerberg G, Duffy SW, Smith TC. Recent results from the Swedish Two-County Trial. The effects of age, histologic type, and mode of detection on the efficacy of breast cancer screening. J Natl Cancer Inst. 1997;22:43-7.
10. Fletcher SW. Breast cancer screening among women in their forties: an overview of the issues. J Natl Cancer Inst. 1997;22:5-9.
11. Kerlikowske K. Efficacy of screening mammography among women aged 40-49 years and 50-69 years. Comparison of relative and absolute benefit. J Natl Cancer Inst. 1997;22:79-86.
12. Fletcher SW, Elmore JG. Clinical practice. Mammographic screening for breast cancer. N Engl J Med. 2003;348:1672-80.
13. Mezetti M, La Vecchia C, Decarli A, Boyle P, Talamini R, Franceschi S. Population attributable risk for breast cancer: diet, nutrition and physical exercise. J Natl Cancer Inst. 1998;90:389-93.
14. Gammon MD, Schoenberg JB, Britton JA, et al. Recreational physical activity and breast cancer risk among women under age 45 years. Am J Epidemiol. 1998;147:273-80.
15. Huang Z, Hankinson SE, Colditz GA, et al. Dual effects of weight and weight gain on breast cancer risk. JAMA. 1997;278:1407-11.
16. Smith-Warner S, Spiegelman D, Yaun S-S, et al. Alcohol and breast cancer in women. A pooled analysis of cohort studies. JAMA. 1998;279:535-9.
17. Kallioniemi A. Molecular signatures of breast cancer - predicting the future. N Engl J Med. 2002;347:2067-8.
18. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81:1879-86.
19. Lurie N, Margolis KL, Mink PJ, Slater JS. Why do patients of female physicians have higher rate of breast and cervical cancer screening? J Gen Intern Med. 1997;12:34-43.
20. Herman CJ, Lengerich EJ, Stood G. Variation in recommendations for breast and cervical cancer screening among primary care physicians in North Carolina. South Med J. 1996;89:583-90.
21. Howe HL, Katterhagen JG. Effects of physician outreach programs on rural-urban differences in breast cancer management. J Rural Health. 1997;13:109-17.
22. Nattinger AB, Gottlieb MS, Veum J, Yahnke D, Goodwin JS. Geographic variation in the use of breast-conserving treatment for breast cancer. N Engl J Med. 1992;326:1102-7.
23. Ernster VL, Barclay J, Kerlikowske K, Grady D, Henderson C. Incidence of and treatment for ductal carcinoma in situ of the breast. JAMA. 1996;275:913-8.
24. Morrow M, Strom EA, Bassett LW, et al. Standard for the management of ductal carcinoma in situ of the breast (DCIS). CA Cancer J Clin. 2002;52:256-76.
25. Kerlikowske K, Molinaro A, Cha I, et al. Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy. J Natl Cancer Inst. 2003;95:1692-702.
26. Lipsitz SR, Fitzmaurice GM, Orav EJ, Laird NM. Performance of generalized estimating equations in practical situations. Biometrics. 1994;50:270-8.
27. U.S. Preventive Services Task Force. 2002. Available at: http://www.ahcpr.gov/clinic/uspstfix.htm. Accessed February 27, 2004.
28. Kerlikowske K, Grady D, Rubin SM, Sandrock C, Ernster VL. Efficacy of screening mammography. A meta-analysis. JAMA. 1995;273:149-54.
29. Willet WC, Browne ML, Bain C. Relative weight and risk of breast cancer among premenopausal women. Am J Epidemiol. 1985;122:731-9.
30. Hunter DJ, Willett WC. Nutrition and breast cancer. Cancer Causes Control. 1996;7:56-68.
31. Pathak DR, Whittemore AS. Combined effects of body size, parity and menstrual events on breast cancer incidence in seven countries. Am J Epidemiol. 1992;135:153-67.
32. Hankinson SE, Willet WC, Manson JE. Alcohol, height, and adiposity in relation to estrogen and prolactin levels in postmenopausal women. J Natl Cancer Inst. 1995;87:1297-302.
33. Sakorafas GH. The management of women at high risk for the development of breast cancer: risk estimation and preventative strategies. Cancer Treat Rev. 2003;29:79-89.
34. Ernster VL, Ballard-Barbash R, Barlow WE, et al. Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst. 2002;94:1546-54.
35. Ernster VL, Barclay J, Kerlikowske K, Wilkie H, Ballard-Barbash R. Mortality among women with ductal carcinoma in situ of the breast in the population-based surveillance, epidemiology and end results program. Arch Intern Med. 2000;160:953-8.
36. Wideroff L, Freedman AN, Olson L, et al. Physician use of genetic testing for cancer susceptibility: results of a national survey. Cancer Epidemiol Biomarkers Prev. 2003;12:295-303.
37. Cuzick J, Forbes J, Edwards R, et al. First results from the International Breast Cancer Intervention Study (IB1S-I): a randomized prevention trial. Lancet. 2002;360:817-24.
38. Freedman AN, Graubard BI, Rao SR, McCaskill-Stevens W, Ballard-Barbash R, Gail MH. Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention. J Natl Cancer Inst. 2003;95:526-32.
39. Schrag D, Kuntz KM, Garber JE, Weeks JC. Decision analysis - effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med. 1997;336:1465-71.
40. Kinney AY, Richards C, Vernon SW, Vogel VG. The effect of physician recommendation on enrollment in the breast cancer chemoprevention trial. Prev Med. 1998;27(5 Part 1):713-9.
41. Fox SA, Siu AL, Stein JA. The importance of physician communication on breast cancer screening of older women. Arch Intern Med. 1994;154:2058-68.
42. Armstrong K, Stopfer J, Calzone K, Fitzgerald G, Coyne J, Weber B. What does my doctor think? Preferences for knowing the doctor's opinion among women considering clinical testing for BRCA1/2 mutations. Genet Test. 2002;6:115-8.
43. Yarnall KS, Pollak KI, Ostbye T, Krause KM, Michener JL. Primary care: is there enough time for prevention? Am J Public Health. 2003;93:635-41.
44. Houn F, Helzlsouer KJ, Friedmna NB, Stefanek ME. The practice of prophylactic mastectomy. A survey of Maryland surgeons. Am J Public Health. 1995;85:801-5.
45. Frank E, Rock J, Sara D. Characteristics of female obstetrician- gynecologists in the United States. Obstet Gynecol. 1999;94(5 Part 1):659-65.
46. Gandhi TK, Francis EC, Puopolo AL, Burstin HR, Haas JS, Brennan TA. Inconsistent report cards: assessing the comparability of various measures of the quality of ambulatory care. Med Care. 2002;40:155-65.